Characterization of ^sup 64^Cu-DOTA-Conatumumab: A PET Tracer for In Vivo Imaging of Death Receptor...
Characterization of ^sup 64^Cu-DOTA-Conatumumab: A PET Tracer for In Vivo Imaging of Death Receptor 5
About this item
Full title
Author / Creator
Publisher
New York: Society of Nuclear Medicine
Journal title
Language
English
Formats
Publication information
Publisher
New York: Society of Nuclear Medicine
Subjects
More information
Scope and Contents
Contents
Conatumumab is a fully human monoclonal antibody that binds to and activates human death receptor 5 (DR5; also known as TRAIL receptor 2). The purpose of this study was to characterize ^sup 64^Cu-labeled conatumumab as a PET tracer for imaging DR5 in tumors. Methods: DOTA-conatumumab was synthesized by incubating conatumumab with 2,2',2''-(10-(2-(2...
Alternative Titles
Full title
Characterization of ^sup 64^Cu-DOTA-Conatumumab: A PET Tracer for In Vivo Imaging of Death Receptor 5
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_871723023
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_871723023
Other Identifiers
ISSN
0161-5505
E-ISSN
1535-5667
